Gilead leads rivals in race to cure hepatitis C

Home › Gilead leads rivals in race to cure hepatitis C

Gilead Sciences' Sovaldi can cure as many as 90 percent of hepatitis C patients in 12 to 24 weeks.

03.07	Hurricane Beryl Graphics
03.07	Hurricane Beryl Public Advisory Number 18A
03.07	Summary for Hurricane Beryl (AT2/AL022024)
03.07	Eastern North Pacific Tropical Weather Outlook
03.07	Atlantic Tropical Weather Outlook
03.07	Benefits of benchmarking in the pork industry
03.07	Hurricane Beryl Graphics
03.07	Hurricane Beryl Forecast Discussion Number 18
More »

je.st